| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $650,000 ) |
| | 2024 | 2024 | TARGETED THERAPY TECHNOLOGIES, LLC | 16 TECHNOLOGY DR STE 134 | IRVINE | CA | 92618-2326 | ORANGE | USA | R01FD008443 | Retinoblastoma Phase II Expanded Access Clinical Trial | 000 | 1 | FDA | 9/16/2024 | $650,000 |
| | 2024 | 2022 | TARGETED THERAPY TECHNOLOGIES, LLC | 16 TECHNOLOGY DR STE 134 | IRVINE | CA | 92618-2326 | ORANGE | USA | R01FD005388 | Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma | 000 | 3 | FDA | 4/29/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $220,000 ) |
| | 2022 | 2022 | TARGETED THERAPY TECHNOLOGIES, LLC | 16 TECHNOLOGY DR STE 134 | IRVINE | CA | 92618-2326 | ORANGE | USA | R01FD005388 | Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma | 000 | 3 | FDA | 7/25/2022 | $61,401 |
| | 2022 | 2022 | TARGETED THERAPY TECHNOLOGIES, LLC | 16 TECHNOLOGY DR STE 134 | IRVINE | CA | 92618-2326 | ORANGE | USA | R01FD005388 | Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma | 000 | 3 | FDA | 7/25/2022 | $158,599 |
|
| Issue Date FY: 2021 ( Subtotal = $220,000 ) |
| | 2021 | 2021 | TARGETED THERAPY TECHNOLOGIES, LLC | 3972 BARRANCA PKWY STE J 185 | IRVINE | CA | 92606-1204 | ORANGE | USA | R01FD005388 | Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma | 000 | 2 | FDA | 7/29/2021 | $220,000 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | TARGETED THERAPY TECHNOLOGIES, LLC | 3972 BARRANCA PKWY STE J 185 | IRVINE | CA | 92606-1204 | ORANGE | USA | R01FD005388 | Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma | 000 | 1 | FDA | 7/31/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $220,000 ) |
| | 2019 | 2019 | TARGETED THERAPY TECHNOLOGIES, LLC | 3972 BARRANCA PKWY STE J 185 | IRVINE | CA | 92606-1204 | ORANGE | USA | R01FD005388 | Phase I Clinical Investigation of Episcleral Topotecan in Retinoblastoma | 000 | 1 | FDA | 8/5/2019 | $220,000 |
|
| Issue Date FY: 2013 ( Subtotal = $0 ) |
| | 2013 | 2010 | TARGETED THERAPY TECHNOLOGIES LLC | 3972 BARRANCA PARKWAY | IRVINE | CA | 92606 | ORANGE | USA | RC3CA150730 | EPISCLERAL CHEMOTHERAPY AS SALVAGE THERAPY FOR EYES WITH RETINOBLASTOMA | 000 | 1 | NIH | 8/13/2013 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $2,769,464 ) |
| | 2010 | 2010 | TARGETED THERAPY TECHNOLOGIES LLC | 3972 BARRANCA PARKWAY | IRVINE | CA | 92606 | ORANGE | USA | RC3CA150730 | EPISCLERAL CHEMOTHERAPY AS SALVAGE THERAPY FOR EYES WITH RETINOBLASTOMA | 000 | 1 | NIH | 9/27/2010 | $2,769,464 |
|
|
